Table 2 Constituents of commercially available PCCs in Europe (based on product labeling*)
Factor content | Antithrombotic content | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
II | VII | IX | X | Protein C, S, Z (label IU/ml) | |||||||||
Product (manufacturer); international availability | Label IU/ml | Ratio | Label IU/ml | Ratio | Label IU/ml | Ratio | Label IU/ml | Ratio | C | S | Z | ATIII (label IU/ml) | Heparin (label IU/ml) |
Beriplex P/N (CSL Behring); major western European countries | 20–48 | 133% | 10–25 | 69% | 20–31 | 100% | 22–60 | 161% | 15–45 | 13–26 | Not in label | 0.2–1.5 | 0.4–2.0 |
Octaplex (Octapharma); major western European countries | 11–38 | 98% | 9–24 | 66% | 25 | 100% | 18–30 | 96% | 7–31 | 7–32 | Not in label | Not in label | Not in label |
Prothromplex Total/S-TIM 4 Immuno (Baxter); Sweden, Germany, Austria | 30 | 100% | 25 | 83% | 30 | 100% | 30 | 100% | >20 | Not in label | Not in label | 0.75–1.5 | <15 |
Prothromplex TIM 3 (Baxter); Italy, Austria | 25 | 100% | Not in label | - | 25 | 100% | 25 | 100% | Not in label | Not in label | Not in label | Not in label | 3.75 |
Cofact/PPSB SD (Sanquin/CAF); Netherlands, Belgium, Austria, Germany | ≥ 15 | 75% | ≥ 5 | 25% | ≥ 20 | 100% | ≥ 15 | 75% | Not in label | Not in label | Not in label | Present, not quantified | Not in label |
Kaskadil (LFB); France | 40 | 160% | 25 | 100% | 25 | 100% | 40 | 160% | Not in label | Not in label | Not in label | Not in label | Present, not quantified |
Uman Complex DI (Kedrion); Italy | 25 | 100% | Not in label | 0% | 25 | 100% | 20 | 80% | Not in label | Not in label | Not in label | Present, not quantified | Present, not quantified |
PPSB-human SD/Nano (Octapharma); Germany | 25–55 | 130% | 7.5–20 | 45% | 24–37.5 | 100% | 25–55 | 130% | 20–50 | 5–25 | Not in label | 0.5–3 | 0.5–6 |